TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS WITH UKALLXII PROTOCOL
Abstract
BACKGROUND The prognosis of acute lymphoblastic leukemia (ALL) in adults is far worse than that inchildren in terms of induction of complete remision (61–85 %) and leukemia-free survival3–5 years (35 %). The UKALL XII regiment was studied at the Department of Haematology, Universitiy Medical Centre Ljubljana.Patients and Between January 2000 and December 2007 41 adults patients with newly diagnosed ALLmethods were eligible for induction chemotherapy (UKALL XII regiment). The median age of thepatients was 33 years, range 17–68 years. We conducted 18 hematopoietic cell transplantation (HCT), including 9 avtologous, 5 related donor HCT and 4 unrelated donor HCT. RESULTS 33 patients (81 %) achieved complete remission. Overall 5-year survival in all patients was48 %. In those younger than 30 years in was 66 % and in those older than 30 years it was38 %. 4 patients (10 %) died within 6 weeks of diagnosis. The cause of mortality proved tobe infection. CONCLUSIONS The UKALL XII regiment is an aggressive approach. We conclude that cytogenetics is astrong independent prognostic factor. In most patients we can achieve a complete remission, but most patients relapse. Therefore allogeneic HCT or prolonged consolidation andmaintainance tretment is warranted. There is probable no benefit of avtologous HCT inpatients with ALLDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
